Aveanna Healthcare (AVAH) Stock Price, News & Analysis

Company Overview

Aveanna Healthcare Corporation is a provider of home-based healthcare services for children, adults and families in the United States. The company’s services are designed to help patients receive medical and supportive care in their homes and communities, including individuals with complex, chronic or medically fragile conditions.

Aveanna’s principal services include private-duty nursing, home health, hospice and personal care. It also provides pediatric therapy and related clinical services, including physical, occupational and speech therapy. Through these offerings, the company supports patients with skilled nursing needs, rehabilitation requirements, chronic illnesses and end-of-life care.

Headquartered in Atlanta, Georgia, Aveanna serves patients across a broad network of states in the U.S. The company was formed through the combination of healthcare businesses including Epic Health Services and PSA Healthcare and became a publicly traded company on the Nasdaq under the symbol AVAH in 2021. Aveanna is led by Chief Executive Officer Jeff Shaner.

Key Stats

• Today's Range: $13.88 to $14.54
• 50-Day Range: $8.95 to $14.08
• 52-Week Range: $5.93 to $14.54
• Volume: 2.37 million shs
• Average Volume: 3.36 million shs
• Market Capitalization: $3.07 billion
• P/E Ratio: 11.45
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Moderate Buy

Aveanna Healthcare Stock Analysis - MarketRank™

Aveanna Healthcare scored higher than 77% of companies evaluated by MarketBeat, and ranked 201st out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aveanna Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 6 buy ratings, 5 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Aveanna Healthcare is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Aveanna Healthcare has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 12.00%

Earnings Growth

Earnings for Aveanna Healthcare are expected to grow by 12.00% in the coming year, from $0.75 to $0.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aveanna Healthcare is 11.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.18.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aveanna Healthcare is 11.45, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.24.

Price to Earnings Growth Ratio

Aveanna Healthcare has a PEG Ratio of 0.89. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Aveanna Healthcare has a P/B Ratio of 15.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.66% of the float of Aveanna Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Aveanna Healthcare has a short interest ratio ("days to cover") of 1.39, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aveanna Healthcare has recently increased by 2.67%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aveanna Healthcare does not currently pay a dividend.

Dividend Growth

Aveanna Healthcare does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.45

News Sentiment

Aveanna Healthcare has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Aveanna Healthcare this week, compared to 5 articles on an average week.

Search Interest

Only 17 people have searched for AVAH on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Aveanna Healthcare to their MarketBeat watchlist in the last 30 days. This is a decrease of -73% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aveanna Healthcare insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $649,301,514.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of Aveanna Healthcare is held by insiders.

Percentage Held by Institutions

87.96% of the stock of Aveanna Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/14/2026
• 2026 Jefferies Healthcare Services and Technology Conference: 9/15/2026
• Deutsche Bank 2026 Healthcare Summit: 9/16/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:AVAH
• CIK: 1832332
• Web: www.aveanna.com
• Phone: 770-441-1580
• Fax: N/A
• Employees: 35,500
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Aveanna Healthcare: $13.50
• High Price Target: $16.00
• Low Price Target: $10.00
• Potential Upside/Downside: -4.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.23
• Trailing P/E Ratio: 11.45
• Forward P/E Ratio: 18.77
• P/E Growth: 0.89
• Net Income: $225.03 million
• Net Margins: 10.56%
• Pretax Margin: 5.92%
• Return on Equity: 80.70%
• Return on Assets: 7.42%

Debt

• Debt-to-Equity Ratio: 4.47
• Current Ratio: 1.16
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: $2.43 billion
• Price / Sales: 1.26
• Cash Flow: $0.69 per share
• Price / Cash Flow: 20.42
• Book Value: $0.93 per share
• Price / Book: 15.14

Miscellaneous

• Outstanding Shares: 218,220,000
• Free Float: 206,654,000
• Market Cap: $3.07 billion
• Optionable: Optionable
• Beta: 1.97